Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Bicycle Therapeutics (NASDAQ: BCYC) has announced the granting of inducement awards to eight new employees on March 3, 2025. The awards, approved by the Compensation Committee under the company's 2024 Inducement Plan, consist of non-qualified share options to purchase 73,700 ordinary shares.
The options have an exercise price of $10.97 per share, matching Bicycle's closing price on February 28, 2025. The vesting schedule spans four years, with 25% vesting after one year and the remaining shares vesting monthly over 36 months, contingent on continued employment. These grants were made in accordance with Nasdaq Listing Rule 5635(c)(4).
Bicycle Therapeutics (NASDAQ: BCYC) ha annunciato l'assegnazione di premi di incentivazione a otto nuovi dipendenti il 3 marzo 2025. I premi, approvati dal Comitato per la Compensazione nell'ambito del Piano di Incentivazione 2024 dell'azienda, consistono in opzioni su azioni non qualificate per l'acquisto di 73.700 azioni ordinarie.
Le opzioni hanno un prezzo di esercizio di $10.97 per azione, corrispondente al prezzo di chiusura di Bicycle del 28 febbraio 2025. Il piano di maturazione si estende su quattro anni, con il 25% che matura dopo un anno e le restanti azioni che maturano mensilmente per 36 mesi, a condizione di un'occupazione continuativa. Questi premi sono stati concessi in conformità con la Regola di Quotazione Nasdaq 5635(c)(4).
Bicycle Therapeutics (NASDAQ: BCYC) ha anunciado la concesión de premios de incentivo a ocho nuevos empleados el 3 de marzo de 2025. Los premios, aprobados por el Comité de Compensación bajo el Plan de Incentivo 2024 de la compañía, consisten en opciones de acciones no calificadas para comprar 73,700 acciones ordinarias.
Las opciones tienen un precio de ejercicio de $10.97 por acción, igualando el precio de cierre de Bicycle del 28 de febrero de 2025. El calendario de adquisición se extiende a lo largo de cuatro años, con un 25% adquiriendo derechos después de un año y las acciones restantes adquiriendo derechos mensualmente durante 36 meses, condicionado a la continuación del empleo. Estas concesiones se realizaron de acuerdo con la Regla de Cotización Nasdaq 5635(c)(4).
바이시클 테라퓨틱스 (NASDAQ: BCYC)는 2025년 3월 3일에 8명의 신규 직원에게 유인 보상을 부여했다고 발표했습니다. 이 보상은 회사의 2024 유인 계획에 따라 보상 위원회에서 승인된 것으로, 73,700주를 구매할 수 있는 비자격 주식 옵션으로 구성됩니다.
옵션의 행사 가격은 $10.97로, 2025년 2월 28일 바이시클의 종가와 일치합니다. 권리 확정 일정은 4년 동안 진행되며, 1년 후 25%가 확정되고 나머지 주식은 36개월 동안 매월 확정됩니다. 이는 지속적인 고용을 조건으로 합니다. 이러한 보상은 나스닥 상장 규칙 5635(c)(4)에 따라 이루어졌습니다.
Bicycle Therapeutics (NASDAQ: BCYC) a annoncé l'octroi de récompenses d'incitation à huit nouveaux employés le 3 mars 2025. Les récompenses, approuvées par le Comité de Rémunération dans le cadre du Plan d'Incitation 2024 de l'entreprise, consistent en des options d'achat d'actions non qualifiées pour l'achat de 73 700 actions ordinaires.
Les options ont un prix d'exercice de $10.97 par action, correspondant au prix de clôture de Bicycle du 28 février 2025. Le calendrier d'acquisition s'étend sur quatre ans, avec 25 % des actions acquises après un an et les actions restantes acquises mensuellement sur 36 mois, sous réserve d'un emploi continu. Ces attributions ont été faites conformément à la règle de cotation Nasdaq 5635(c)(4).
Bicycle Therapeutics (NASDAQ: BCYC) hat am 3. März 2025 die Gewährung von Anreizprämien an acht neue Mitarbeiter bekannt gegeben. Die Prämien, die vom Vergütungsausschuss im Rahmen des Anreizplans 2024 des Unternehmens genehmigt wurden, bestehen aus nicht qualifizierten Aktienoptionen zum Kauf von 73.700 Stammaktien.
Die Optionen haben einen Ausübungspreis von $10.97 pro Aktie, was dem Schlusskurs von Bicycle am 28. Februar 2025 entspricht. Der Vesting-Zeitplan erstreckt sich über vier Jahre, wobei 25 % nach einem Jahr und die verbleibenden Aktien monatlich über 36 Monate vesten, abhängig von einer fortgesetzten Beschäftigung. Diese Zuwendungen wurden gemäß der Nasdaq-Listing-Regel 5635(c)(4) vorgenommen.
- New employee hiring indicates company growth
- Potential shareholder dilution from 73,700 new shares
Each option has an exercise price equal to
About Bicycle Therapeutics
Bicycle Therapeutics is a clinical-stage pharmaceutical company developing a novel class of medicines, referred to as Bicycle® molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycle molecules attractive candidates for drug development. The company is evaluating zelenectide pevedotin (formerly BT8009), a Bicycle® Toxin Conjugate (BTC®) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC molecule targeting EphA2, a historically undruggable target; and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist® (Bicycle TICA®) targeting Nectin-4 and agonizing CD137, in company-sponsored clinical trials. Additionally, the company is developing Bicycle® Radio Conjugates (BRC®) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle® technology to develop therapies for diseases beyond oncology.
Bicycle Therapeutics is headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20250305899640/en/
Investors:
Stephanie Yao
SVP, Investor Relations and Corporate Communications
stephanie.yao@bicycletx.com
857-523-8544
Matthew DeYoung
Argot Partners
ir@bicycletx.com
212-600-1902
Media:
Jim O’Connell
Weber Shandwick
media@bicycletx.com
312-988-2343
Source: Bicycle Therapeutics plc
FAQ
How many shares are included in BCYC's March 2025 inducement grants?
What is the exercise price for BCYC's March 2025 inducement options?
What is the vesting schedule for BCYC's March 2025 inducement options?
How many employees received BCYC inducement grants in March 2025?
